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This report describes various old and new positive ino-
tropic drugs with respect to their mechanisms of action.
Drugs with established cardiotonic effects include car-
diac glycosides, betaj-adrenergic agents, glucagon, his-
tamine and the methylxanthines. New agents discussed
art: prenalterol, betas- and alpha-adrenergic drugs, am-
rinone and sulmazole. Prenalterol is a betaj-adrenergic
agent. Betaj-adrenerglc drugs, amrinone and sulmazole,
combine a positive inotropic and a vasodilator effect.
Agents that increase the force of contraction of the heart
are referred to as positive inotropic or cardiotonic drugs .
The increase in the force of myocardial contraction is ul-
timately due to an increase in intracellular free Ca2 + [Caz+ li
to interact with the contractile proteins or to an increased
sensitivi ty of the myofilaments for Caz+ , or both. This re-
port discusses how these variables might be affected by
various inotropic drugs. Agents with established inotropic
effect, such as cardiac glycosides, beta-adrenergic drugs,
methylxanthines, glucagon and histamine, are described first.
The second part of the report is concerned with new car-
diotonic agents or those still under investigation. These in-
clude prenalterol, beta-adrenergic and alpha-adrenergicdrugs,
arnrinone and sulmazole. For a more comprehensive dis-
cussion of the topic and a more extensi ve bibliograph y, the
reader is referred to several recent reviews (1-6).
Mechanisms Activating Contraction and
Relaxation of Cardiac Muscle
All cardiotonic drugs interact with one or more of the
steps involved in contraction and relaxation of the heart
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The latter resemble theophylline and other methylxan-
thines in that they appear to act mainly as phosphodi-
esterase inhibitors with a subsequent increase in cyclic
adenosine monophosphate (cAMP). The mechanism of
the positive inotropic effect of alpha-adrenergic stimu-
lating agents (for example, phenylephrine) is unknown.
It is independent of the cAMP system and is not accom-
panied by changes in frequency.
(Fig. I) (7-11). Depolarization of the sarcolemma, that is,
the Na + -dependent upstroke of the action potential , is the
initial event. The depolarization of the cell membrane allows
CaZ+ to move down its electrochemical gradient and enter
the cell from the extracellular space during the plateau phase
of the action potential (slow CaZ + inward current [Isil; Fig.
I , step I). The major part of the Caz+ entering the cell
during the action potential serves to fill intracellular stores
(presumably the subsarcolemmal cisternae of the sarco-
plasmic reticulum) and trigger the release of Ca?+ from the
sarcoplasmic reticulum into the cytosol to react with the
contractile proteins (Fig. I, step 2) . The mean rest level of
[Ca2+]i is about 0.3 p.M; the activation of the contractile
proteins requires an increase to above this value with half
maximal and maximal responses occurring at about 2 p.M
and 10 p.M, respectively (12) . Relaxation occurs on low-
ering the [Ca2 +] j to below the rest level. This results from
the uptake of Caz+ by the longitudinal part of the sarco-
plasmic reticulum (Fig. I, step 3). Finally, there is an ex-
trusion of Caz+ to the extracellular space to avoid a Ca! "
overload. This transport of Caz+ out of the cell is achieved
mainly through a CaZ + INa+ exchange system (Fig. 1, step
This article is part ofa continuing series of informal teach-
ing reviews devoted to subjects in basic cardiology that are
of particular interest because of their high potential for
clinical application.
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Figure 1. Schematic summaryof the mech-
anisms leading to contraction and relaxation
in the mammalian heart. I = calciuminflow
into the cell during the action potential;2 =
releaseof calciumfrom subsarcolemmal cis-
ternaeof the sarcoplasmic reticulum (storage
site) and diffusion through the cytosol to the
contractile proteins; 3 = uptake of calcium
into the longitudinal part of the sarcoplasmic
reticulum (relaxation site); 4 = calcium
transport outof the cell through theCa2 +INa+
exchange system; 5 = release of calcium
from and uptakeof calciuminto sarcolemmal
stores; and 6 = the sodium pump (Na" +
K+)-ATPase.
4) that, under equilibrium conditions, follows the equation:
[Ca2 +]. = [Ca2+] [Na+]f exp (n - 2) FV
I 0 [Na+]~ RT'
where n is the number of Na + that exchanges for one Caz+
ion, V is the membrane potential and F, Rand T are the
Faraday constant, the universal gas constant and the absolute
temperature, respectively (13). Its driving force is the con-
centration gradient for Na + across the sarcolemma which,
in tum, is accomplished largely by the sarcolemmal sodium
pump, (Na " + K+)-ATPase (Fig. 1, step 6). The exact
stoichiometry of the Caz+INa + exchange system has not
yet been resolved, but it is important to note in the present
context (especially with respect to the cardiac glycosides)
that only a very small increase in [Na +]i is required to
achieve a relatively large increase in [Ca2+]i and, hence,
in the force of contraction.
A smaller amount of Caz+ efflux may also be mediated
by a sarcolemmal Caz+ pump that uses adenosine triphos-
phate in a fashion analogous to the sodium pump.
Established Cardiotonic Drugs
Cardiac Glycosides
The cardiac glycosides remain the most commonly used
agents for the long-term management of congestive heart
failure. It is generally accepted that these drugs ultimately
lead to an increase in the amount of intracellular Ca' + avail-
able to react with the contractile proteins, but the exact
mechanisms through which this can be achieved are still a
matter of considerable debate (14-17). There is no doubt
that the cardiac glycosides interact with the (Na + + K +)-
ATPase and that this enzyme represents the "cardiac gly-
coside receptor," but the subsequent steps are unsettled.
Inhibition of (Na + + K +)·ATPase activity. Many au-
thors argue that inhibition of (Na + + K +)-ATPase activity
is the most important event. The inhibition of Na + transport
out of the cell results in an increase in the intracellular Na+
concentration which, by way of an effect on the transsar-
colemmal Caz+INa+ exchange described earlier, leads to
an increase in [Ca2+L. In other words, the accumulation of
Na + at the inside of the sarcolemma competitively inhibits
the efflux of Ca!" by way of the Ca2+INa + exchange system
that normally carries Caz+ out of the cell. The result of the
decrease in Ca?+ efflux is an increase in [Caz+Ji. This view
has recently gained considerable support by Lee and Da-
gostino (18) and Wasserstrom et al, (19), who showed through
the use of Na +-sensitive intracellular microelectrodes that
changes in intracellular Na + activity and in twitch tension
produced by therapeutic concentrations of cardiac glyco-
sides were closely correlated. Quantitatively, a 1 mM in-
crease in intracellular sodium activity (which is barely de-
tectable with chemical methods) was accompanied by about
a 100% increase in force of contraction.
Other investigators (15) assume that such an inhibition
of (Na " + K+)-ATPase activity is only important during
toxic actions of these agents. The interaction of therapeutic
concentrations with the (Na" + K+)-ATPase would not
necessarily inhibit the enzyme, but instead could lead to a
less stable Caz+ binding within the sarcolemma and, hence,
to an increased Caz+ release from sarcolemmal Ca2+ stores
during excitation (Fig, 1, step 5). This view, however, is
still highly controversial.
Increase in (lsi)' Another still unresolved question is the
effect of cardiac glycosides on the slow Caz+ inward current
(Is;)' Some authors found that cardiac glycosides increase
Is;, but this was not in accord with reports from others
(20,21), However, the reported increase in lsiapparently did
not result from a direct interaction between drugs and slow
channels, but instead was indirect and resulted from an
increase in [Ca2+L achieved by other mechanisms, More-
over, the changes in Caz+ influx by way of lsidid not appear
to be absolutely required for positive inotropy. Thus, I be-
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lieve that the most plausible mechanism of the cardiotonic
effect (If the cardiac glycosides at present is an increase in
[Ca2+] due to (Na" + K+)-ATPase inhibition and sub-
sequent alteration of Ca2 +INa + exchange.
Beta-Adrenergic Drugs
The positive inotropic effect of the catecholamines nor-
epinephrine, epinephrine, isoproterenol, dopamine and do-
butamine is due mainly to stimulation of myocardial beta,-
adrenoceptors (22-29). The increase in force of contraction
brought about by these agents characteristically develops
very rapidly. Moreover, it is accompanied by an increase
in the rate of force development (positive clinotropic effect)
that is typical of almost all positive inotropic interventions
(with the exception of hypothermia, for example) and is,
therefore, not very distinctive. More important is a decrease
in the duration of the contraction. The latter action is mainly
due to a more rapid relaxation of the contraction and is,
therefore, referred to as the "relaxant effect" of beta-
adrenoceptor stimulation. It is noteworthy that the ability
of the beta-adrenergic drugs to shorten the contraction are
shared only by agents known to increase myocardial cyclic
AMP ( AMP) content. From a functional point of view, the
relaxant effect of beta-adrenergic stimulation is important
in permitting adequate ventricular filling in the face of in-
creased heart rates.
Effects on Ca2+ and cyclic AMP. The mechanism of
the positive inotropic action of beta-adrenergic catechol-
amines has not been elucidated in detail. However, it is
generally accepted that these agents also produce an increase
in Ca2 -t concentration in the vicinity of the contractile pro-
teins, that they lead to an increase in myocardial cAMP
levels, and that the effects on both the Ca2+ and the cAMP
systems are likely to be causally related to each other.
The main effect of the beta-adrenergic agonists on myo-
cardial Ca2 + movements is to increase the slow Ca2 + inward
current during the action potential (Fig. I, step I). This
effect which has been attributed to an increase in the number
of functional Ca2+ channels (30), and more recently, using
the patch clamp method to record current flow through single
channels, to an increase in the probability of Ca2 + channels
to open during depolarization (31). The increase in lsi leads
to an increased Ca2 + release from the sarcoplasmic retic-
ulum (Fig. 1, step 2), either because it serves as a greater
trigger for Ca2+- dependent Ca2 + release or because it in-
creases the filling of these stores with Ca2 + that can be re-
leased during subsequent beats. In addition, beta-adrenergic
agonists lead to an increase in Ca2+ uptake into the sar-
coplasmic reticulum (Fig. 1, step 3), which also increases
the amount of releasable Ca2 + within and an increased Ca2 +
release -'rom these stores. This increase in Ca2+ uptake by
the sarcoplasmic reticulum not only contributes to the pos-
itive inotropic properties, but also explains the relaxant ef-
fects of the beta-adrenergic agonists. However, there is some
evidence that the latter might, in part, also be due to a
decrease in the Ca2 + sensitivity of the contractile proteins
(27).
It is widely accepted that the effects of beta-adrenergic
agonists on myocardial Ca2 + movements are not direct in
nature, but instead are the result of a stimulation of the
adenylate cyclase with a subsequent increase in cAMP lev-
els. cAMP leads to an activation of protein kinases and, as
a result, to phosphorylation of several proteins. This changes
the functional properties of the proteins, for example, their
ability to bind Ca2+ ions, and may thus explain the beta-
adrenergic effects on the calcium movements in the sar-
coplasmic reticulum and possibly also in the sarcolemma.
In summary, the positive inotropic effect of beta-adre-
nergic drugs is mainly the result of an increase in slow Ca2+
inward current and in Ca2 + uptake into the sarcoplasmic
reticulum. This, in tum, is presumably due to a cAMP-
dependent phosphorylation of a variety of functional pro-
teins. Hence, the beta-adrenergic effects on myocardial Ca2+
movements on the one hand and on the cAMP system on
the other are probably causally related in a common pathway
where the beta-adrenergic drug represents the first messen-
ger and cAMP and Ca2+ represent the second and third
messengers, respectively.
Glucagon and Histamine
Glucagon (32) and histamine (33) also have a well
established positive inotropic effect in the heart. This ef-
fect is qualitatively similar to that produced by the beta,-
adrenergic catecholamines and is also related to an in-
creased cAMP level due to stimulation of the adenylate
cyclase. However, the effects of glucagon or histamine are
not mediated by beta-adrenoceptors and are not impaired
by beta-adrenoceptor blocking agents, so that these drugs
can be administered, at least theoretically, after pretreatment
with beta-adrenoceptor blocking drugs. However, the clin-
ical effectiveness of glucagon is not very pronounced and
the therapeutic usefulness of histamine is limited by serious
side-effects.
Methylxanthines
The methylxanthines (especially theophylline) produce
not only positive inotropic, but also vasodilator effects
(6,22,26,34). The former effect of theophylline is similar
to that of the beta-adrenergic agents. It develops very rap-
idly (within a few seconds), is independent of the extra-
cellular Na + and K + concentration, is impaired by calcium
channel blocking agents such as verapamil and is also closely
related to an increase in Ca2+ influx from the extracellular
space (Fig. 1, step 1).
Inhibition of Ca 2+ uptake. The positive inotropic ef-
fect of the methylxanthines has been attributed to: 1) a direct
interaction with intracellular Ca2 + stores (inhibition of Ca2 +
uptake by the sarcoplasmic reticulum), 2) an increase in
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~o) Controlb bl Isobutylmethylxonthineo 0.1 mM
Db 01 ControlfL b) Isoproterenol 0.03 jJM
Figure 2. Effect of isoproterenol, theophylline and 3-isobutyl-l-
methylxanthine at approximately equieffective concentrations on
the isometric contraction of the heart. The curves are redrawn
from original traces obtained in electrically driven (frequency I
Hz) papillary muscles from guinea pigs pretreated with reserpine.
system, for example). In this context, the main argument
is that the inotropic effects of theophylline and adenosine
are opposite only in atria. While the cardiotonic effect of
theophylline is similar in atrial and ventricular preparations,
adenosine is negatively inotropic in the atrium, but not in
ventricular cardiac muscle. In the latter, adenosine does not
change contractile force at concentrations up to 10 IJM, and
higher concentrations of adenosine even produce a slightly
positive inotropic effect (34).
Sensitization of the contractile apparatus to Cal ". This
may also contribute to the cardiotonic effect of the meth-
ylxanthines. Fabiato (39) reported that the Ca2 + sensitivity
of skinned single cardiac cells was increased by caffeine
(20 roM) and theophylline (10 roM). The potential impor-
tance of this effect has also been considered by Morgan and
Blinks (40), who observed that millimolar concentrations
of theophylline produced large inotropic effects without con-
sistently increasing the amplitude of the signal of the Ca2 + -
sensitive bioluminescent protein aequorin. However, apart
from the fact that these effects were again observed only at
relatively high drug concentrations, they have not been ob-
tained by others. Herzig et al. (41), for instance, reported
that theophylline or caffeine in concentrations up to 10 roM
had no effect on the Ca2 + sensitivity of the contractile pro-
teins. This matter therefore remains controversial.
In summary, I believe that the cardiotonic action of theo-
phylline and other methylxanthines, at least at therapeutic
concentrations, is due primarily to their effect to inhibit
phosphodiesterase, and, therefore, to increase cAMP levels.
These effects, together with those of the beta.vadrenergic
catecholamines, glucagon and histamine, are schematically
summarized in Figure 3. It should be noted that the increase
0) Control
b) Theophylline 3 mMJL
cellular cAMP content resulting from an inhibition of phos-
phodiesterase activity, 3) a blockade of receptors for en-
dogenous adenosine (35), and 4) a sensitization of the con-
tractile proteins to Ca2 +. The first possibility is probably
significant only at high concentrations because the effect of
the methylxanthines on the sarcoplasmic reticulum only oc-
curs at concentrations greater than I roM which are not
reached during therapy as maximal therapeutic theophylline
plasma concentrations are 50 to 100 IJM (35).
Increase in cellular cAMP. At therapeutic concentra-
tions, the second mechanism appears to be more likely. The
similarity between the positive inotropic effects of the beta-
adrenergic catecholamines and theophylline suggests that an
increase in myocardial cAMP levels might be involved not
only in the former but also in the latter. In fact, theophylline
has been shown to produce a similarly pronounced enhance-
ment in cAMP content and in force of contraction, and the
increase in cAMP in the presence of theophylline is closely
correlated to an inhibition in phosphodiesterase activity (34).
It is, therefore, reasonable to conclude that the increase in
cAMP in the case of the methylxanthines is due to an in-
hibition of the degradation of cAMP, while the beta-adren-
ergic positive inotropic response is due to an increase in
cAMP formation. In both cases, the increase in cAMP leads
to the increase in slow Ca2 + inward current which, in tum,
finally produces the cardiotonic effect.
This explanation is not necessarily contradicted by the
fact that the classic methylxanthines, caffeine and theophyl-
line, especially at high concentrations, have some effects
that are opposite to those of the beta-adrenergic agonists
(36-38). Most importantly, millimolar concentrations usu-
ally prolong rather than reduce the duration of the contrac-
tion. However, as mentioned, at concentrations of I roM
and more, theophylline and other methylxanthines directly
inhibit the uptake of Ca2 + by the sarcoplasmic reticulum
(Fig. I, step 3). This effect, which is independent of the
cAMP system, counteracts the cAMP-dependent increase
in Ca2 + uptake and leads to a deceleration of relaxation
and, hence, to a prolongation of contraction.
Thus, the prolongation of contraction in the presence of
theophylline does not exclude the possibility that cAMP
serves as a mediator of the positive inotropic effect of the
methylxanthines. Instead, it suggests that the classic meth-
ylxanthines have cAMP-independent "side effects." In ac-
cord with this explanation, the more potent phosphodies-
terase inhibitor, l-methyl-3-isobutylxanthine, which has no
direct action on the sarcoplasmic reticulum, increases the
force of contraction and decreases the duration of contrac-
tion in exactly the same way as beta-adrenergic agents (iso-
proterenol, for example) (Fig. 2).
Adenosine-antagonistic action. It appears unlikely that
the third mechanism mentioned, an adenosine-antagonistic
action, plays a major role in the effect of theophylline on
myocardial force of contraction, although this is probably
of great importance in other systems (in the central nervous
JACC VoL 4, NO.2
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in cAMP and the subsequent increase in slow Ca2 + inward
current and in Ca2 + uptake into the sarcoplasmic reticulum
are the most important common events in all cases, The
agents differ only in the way through which this increase
in myocardial cAMP content is achieved,
New Positive Inotropic Drugs
The Ideal positive inotropic drug should, according to
Opie (21, cause neither tachycardia nor arrhythmias and
should not lead to a greatly increased oxygen demand, An
additional vasodilation would be of advantage, Chronic use
requires sufficiently high oral bioavailability and long du-
ration of action, No pronounced tolerance should develop
after prolonged treatment. The following new cardiotonic
agents are discussed and evaluated in the light of these
criteria,
Prenalterol
Prenalterol (42) is a beta-adrenergic partial agonist with
relatively selective effects on beta.cadrenoceptors. In con-
trast to norepinephrine, epinephrine, isoproterenol, dopa-
mine and dobutamine, the drug can be administered orally
(bioavailability about 45%) and the duration of action is 4
to 6 hours. The positive inotropic effect of prenalterol has
been reported to be more pronounced than its positive chron-
otropic action. That the ratio of inotropic to chronotropic
effect may be greater for prenalterol than for other beta-
adrenergic agents has been attributed to the observation that
the relative amount of beta-adrenoceptors is greater in the
left ventricle than in the right atrium, at least in guinea pigs
and cats (43). This argument, however, should apply to all
beta,-adrenergic drugs and is, therefore, only partially con-
clusive. With respect to therapeutic use, it remains to be
"",, SR
Ca++
Figure3. Schematic summary of the mechanisms of the positive
inotropic effects of beta-adrenergic agents, glucagon, histamine
and theophylline (Theo). All drugs increase the cyclic adenosine
monophosphate (cAMP) level, either throughstimulation of aden-
ylate cyclase (increase in cAMP formation) or through inhibition
of phosphodiesterase (PDE; impairment of cAMP degradation).
The increase in cAMP leads to an increase in slow Ca2 + inward
current and to an increased filling of the sarcoplasmic reticulum
(SR) with releasable Ca2 + and, hence, to an increase in Ca2+
concentration at the contractile proteins (CP). The direct cAMP-
independent inhibitory action of theophylline on Ca2 + uptakeinto
the sarcoplasmic reticulum is probably responsible for the the-
ophylline-produced increase in the duration of the contraction.
ATP = adenosine triphosphate; ECS = extracellular space; ICS
= intracellular space.
demonstrated whether prenalterol is still effective after chronic
application (tolerance?) and whether and to what extent the
drug may produce tachyarrhythmias.
Betas-Adrenergic Drugs
Salbutamol (44), terbutaline (45), fenoterol (46) and pir-
buterol (47) interact mainly with betaj-adrenoceptors and
are preferentially used in patients with bronchial asthma.
They produce positive inotropic effects (possibly due to
residual beta-adrenoceptor stimulation) and vasodilation.
It is not clear which of these actions predominates in patients
with myocardial insufficiency. In any case, the vasodilator
effect of these drugs contributes to the increase in cardiac
index and is probably of greater clinical importance than
the direct cardiostimulatory action. The positive chrono-
tropic effect of these agents is claimed to be relatively small.
These drugs may be given orally (bioavailability 40 to 85%)
and their duration of action is 4 to 8 hours. As in the case
of prenalterol, the questions of potential tachyarrhythmias
caused by cardiostimulation and of persistence of the ther-
apeutic effect are not yet resolved.
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Alpha-Adrenergic Drugs
There is no doubt that the positive inotropic response to
adrenergic agents in the heart is mediated predominantly by
beta-adrenoceptors. However, there is increasing evidence
that alpha-adrenoceptors also exist in the myocardium and
that an increase in force of contraction may be produced by
stimulation of these sites (26,48-50). These are alphal-
adrenoceptors, and the most important drugs of this group
used experimentally are phenylephrine and methoxamine .
The principle of an alpha-adrenoceptor-mediated cardi-
otonic action appears promising, but it should be stressed
that the agents hitherto available have as yet not been used
clinically for this purpose, largely because of their predom-
inant vasoconstrictor action.
The positive inotropic effect of alpha-adrenergic agents
is qualitatively different from that of beta-adrenergic drugs.
The alpha-adrenergic response develops relatively slowly
and is accompanied by a prolongation, rather than a short-
ening, of the contraction. Thus, alpha-adrenergic agents do
not produce relaxant effects . Moreover, the alpha-adren-
ergic positive inotropic effect is not accompanied by distinct
chronotropic effects, and is particularly pronounced at low
stimulation frequencies, in hypothermia and in hypo-
thyroidism.
The mechanism of the alpha-adrenergic positive inotropic
response is unknown. It is generally accepted , however,
that there is no increase in cAMP levels, quite in accord
with the observation that there is no relaxant effect. Cyclic
guanosine monophosphate (cGMP) levels and (Na" + K 'f-)_
ATPase activity also remain unchanged. Some investigators
(51) have observed a small increase in slow Ca2 + inward
current which, however , has not been observed in all species
and which is less pronounced than that produced by beta-
adrenoceptor stimulating agents .
The biologic significance of alpha-adrenergic stimulation
in cardiac muscle remains to be established. There is evi-
dence that the alpha-adrenoceptors of the heart differ from
those of other tissues . Thus , it appears conceivable that
drugs that are positively inotropic through stimulation of
myocardial alpha-adrenoceptors without vasoconstrictor ef-
fects will become available for clinical use. From the phys-
iologic point of view, the alpha-adrenergic positive inotropic
effects of catecholamines may be important under conditions
where the stimulation of beta-adrenoceptors is relatively
small (in hypothyroidism, hypothermia and at low heart
rates).
Amrinone
Arnrinone is a bipyridine derivative with positive ino-
tropic, positive chronotropic and vasodilator effects (52) .
The positive inotropic effect develops rapidly within several
minutes and the duration of action is 60 to 90 minutes. It
is not impaired by beta- and alpha-adrenoceptor blocking
agents, or reserpine pretreatment and histamine (HI and H2) -
receptor blocking drugs . Farah (53) Alousi (54) and their
Table 1. Drugs With Positive Inotropic Effects and Their Main Mechanisms of Action
Drug
Cardiac glycosides
BetaI-adrenergic drugs
Norepinephrine
Epinephrine
Isoproterenol
Dopamine
Dobutamine
Glucagon and histamine
Methylxanthines
Caffeine
Theophylline
Prenalterol
Beta--adrenergic drugs
Salbutamol
Terbutaline
Fenoterol
Pirbuterol (Pfizer)
Alpha-adrenergic drugs
Phenylephrine
Amrinone (Winthrop)
Sulmazole (AR-L lIS BS, Thomae)
Mechanism
Reaction with (Na" + K+)-ATPase. subsequent steps unsettled
Increased cAMP level due to stimulation of adenylate cyclase, increase in lsi and Ca2 + uptake by
sarcoplasmic reticulum
Increased cAMP level due to stimulation of adenylate cyclase ; effect similar to that of beta-adrenergic
drugs but independent of beta-adrenoceptor
Increased cAMP level due to inhibition of phosphodiesterase; effect similar to that of beta i-adrenergic
drugs (except lack of relaxant effect) but independent of beta-adrenoceptor: no evidence for adenosine
antagonism
Beta-adrcnoceptor stimulation, chronotropic effect relatively small ; bioavailability 45%, duration of action
4 to 6 hours
Positive inotropic and vasodilatation, bioavailability 40 to 85%, duration of action 4 to 8 hours
Positive inotropic effect , no chronotropic effect ; no relaxant effect ; no effect on cAMP
Phosphodiesterase inhibitor; similar to theophylline; positive inotropic effect and vasodilation
Phosphodiesterase inhibitor; similar to theophylline; possible effect on Ca2 + sensitivity of contractile
proteins; positive inotropic effect and vasodilation
JACC Vol. 4, No. 2
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coworkers initially reported that amrinone also does not
change phosphodiesterase and (Na + + K +)-ATPase activ-
ities or cAMP levels . This led several investigators to con-
clude that amrinone has an entirely new although as yet
unknown mechanism of action. However , Honerjager (55)
and Endoh (56) and their coworkers showed recently that
the positive inotropic effect of amrinone is accompanied by
an inhibition of phosphodiesterase and an increase in cAMP .
Moreover, amrinone potentiated the effects of isoprenaline
and histamine and increased the rate of increase of Ca2 + -
dependent slow action potentials. From these effects , it is
reasonable to assume that amrinone is not a novel drug, but
is instead a phosphodiesterase inhibitor with an action sim-
ilar to that of theophylline. This does not exclude the pos-
sibility that other effects could emerge (57), but the simi-
larity between amrinone and theophylline is important because
any theophylline-like drug must be regarded as a potential
inducer of tachyarrhythmias . At high concentrations, am-
rinone produced a prolongation of the contraction . This
effect is also shared by theophylline , as noted earlier.
Milrinone is a recently developed derivative of amrinone
which is 10 to 30 times more potent than the parent com-
pound . but otherwise appears to possess a similar phar-
rnacologic profile and a similar cAMP-increasing action
(58-60). However, since in the study of Alousi et al. (58)
the rnilrinone-induced increase in force of contraction de-
veloped faster than the increase in cAMP , mechanisms other
than phosphodiesterase inhibition may also be involved in
the cardiotonic effect of this agent.
Sulmazole
Sulrnazole (the former AR-L 115 BS) is a benzimidazole
derivative with positive inotropic, positive chronotropic and
vasodilator effects (61). These effects, which are similar to
those of beta--adrenergic agents , methylxanthines and am-
rinone as discussed earlier, occur at concentrations of 30 to
1,000 pM. They are rapid in onset and last for 20 to 100
minutes.
The positive inotropic effect of sulmazole is not due to
a direct stimulation of beta-adrenoceptors, a release of en-
dogenou s catecholamines, or an interaction with the cardiac
glycoside receptor. Instead , the effect of sulmazole also
resembles largely the effects of the classic methylxanthines,
caffeine and theophylline. For instance , the drug produces
contractures and prolongs the contraction at high concen-
trations; it inhibits phosphodiesterase activity and poten-
tiates the positive inotropic effects of noradrenaline. This
support s the existence of a causal relation between the pos-
itive inotropic effect, inhibition of phosphodiesterase and
an increase in cAMP level. However , it should be pointed
out that the positive inotropic effect of sulmazole appears
not to be due solely to inhibition of phosphodiesterase. It
has been shown experimentally that the drug in a therapeutic
concentration (350 J-lM) increases the Ca2 + sensitivity of
the contractile proteins (4 1), an effect that might contribute
to the positive inotropic action of the drug. Herzig et al.
(4 1) emphasized that sulmazole would be the first example
where a change in Ca2 + sensitivity of the myofilaments
contributes to the positive inotropic effect of a cardiostim-
ulatory agent. However, whether or not this effect is unique
is still a matter of debate , as discussed earlier in the case
of the methylxanthines . But it should be noted that in the
study of Herzig et al. (4 1), theophylline or caffeine in con-
centrat ions of up to 10 roM and amrinone in concentrations
of up to 350 pM failed to produce any effect on the Ca2 +
sensitivity of the contractile proteins .
Conclusions. This brief review has attempted to classify
various old and new positive inotropic drugs according to
their mechanisms of action. The major effects involved are
summarized in Table 1. The inotropic properties of many
of the agents discussed are related to an increase in myo-
cardial cAMP levels, although these are brought about by
different mechanisms. This is important as an increase in
cAMP may potentially lead to tachyarrhythmias. Among
the new inotropic agents , no drug appears to provide major
advantages. The potential development of tolerance during
chronic treatment and the occurrence and significance of
possible side effects appear to be the most significant un-
resolved questions.
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